tetano
Editor, Senior Moderator
Health Sci Rep
. 2026 Apr 20;9(4):e72390.
doi: 10.1002/hsr2.72390. eCollection 2026 Apr.
Different SARS-CoV-2 Subvariants and Coagulation Markers Trend: A Retrospective Multicentric Study From Iranian Network for Research in Viral Diseases (INRVD)
Alireza Razavi[SUP] 1 [/SUP], Masoud Pourghahramani Koltapeh[SUP] 2 [/SUP], Tina Nazari[SUP] 3 [/SUP], Arefe Morvaridi[SUP] 4 [/SUP], Behrooz Banivaheb[SUP] 5 6 7 [/SUP], Sepideh Saeb[SUP] 8 [/SUP], Melina Moulaeian[SUP] 9 [/SUP], Alireza Zakaryaei[SUP] 10 [/SUP], Arash Sabzalian[SUP] 11 [/SUP], Maedeh Raei[SUP] 12 [/SUP], Bahar Razavi[SUP] 13 [/SUP], Saeed Motlaghzadeh[SUP] 14 [/SUP], Somayeh Sadat Hosseini[SUP] 15 [/SUP], Hassan Karami[SUP] 15 [/SUP], Parsa Ghafari[SUP] 15 [/SUP], Amir Aboofazeli[SUP] 15 [/SUP], Sogol Nastarvand[SUP] 9 [/SUP], Negin Kaseb Navaz Sarabi[SUP] 9 [/SUP], Alex Avakian[SUP] 9 [/SUP], Sara Ebadinejad[SUP] 16 [/SUP], Tara Keyhani[SUP] 17 [/SUP], Parand Danafar[SUP] 18 [/SUP], Rozhin Rahimlou[SUP] 19 [/SUP], Sedigheh Heidarian[SUP] 20 [/SUP], Mozhgan Mondeali[SUP] 21 [/SUP], Fatemeh Nafe-Monfared[SUP] 2 [/SUP], Mobina Jafarpour[SUP] 2 [/SUP], Marziyeh Samiee[SUP] 22 [/SUP], Fatemeh Birang[SUP] 22 [/SUP], Amirhossein Mirzazadeh[SUP] 22 [/SUP], Seyed Ariana Feiz Abadi[SUP] 22 [/SUP], Khabat Barkhordari[SUP] 2 [/SUP], Saba Siavoshi[SUP] 23 [/SUP], Mahdi Biklari[SUP] 24 [/SUP], Mohammad Khodabakhsh[SUP] 24 [/SUP], AmirHossein Javadi[SUP] 24 [/SUP], Samaneh Mirzaee[SUP] 2 [/SUP], Farshideh Didgar[SUP] 25 [/SUP], Mostafa Etebari[SUP] 25 [/SUP], Saedeh Soltanmohamad[SUP] 25 [/SUP], Babak Shahbaz[SUP] 2 [/SUP], Ebrahim Kord[SUP] 26 [/SUP], Seyed Mohammad Hashemi Shahri[SUP] 26 [/SUP], Majid Ebrahimzade[SUP] 26 [/SUP], Alireza Ansari Moghaddam[SUP] 27 [/SUP], Fariba Shahraki Sanavi[SUP] 27 [/SUP], Afagh Moattari[SUP] 28 [/SUP], Fahime Edalat[SUP] 28 [/SUP], Majid Fardi Sheijani[SUP] 28 [/SUP], Mohsen Moghadami[SUP] 29 [/SUP], Tofigh Yaghubi[SUP] 30 [/SUP], Ali Mojtahedi[SUP] 31 [/SUP], Abtin Heidarzadeh[SUP] 32 [/SUP], Mohammadreza Naghipour[SUP] 33 [/SUP], Maryam Sharifi Luyeh[SUP] 34 [/SUP], Pershang Nazemi[SUP] 35 [/SUP], Kian Alipasandi[SUP] 36 [/SUP], Maryam Albaji[SUP] 37 [/SUP], Mahdieh Afzali[SUP] 38 [/SUP], Nasim Shokouhi[SUP] 39 [/SUP], Akram Ezani[SUP] 40 [/SUP], Hamid Reza Najari[SUP] 41 [/SUP], Mirshamsedin Hosseini[SUP] 42 [/SUP], Arefeh Ghobadi[SUP] 42 [/SUP], Abdoalmabood Momeni[SUP] 42 [/SUP], Seyedeh Zeinab Fattahi[SUP] 42 [/SUP], Mehdi Mohsenzadeh[SUP] 43 [/SUP], Mohammad Jafari[SUP] 43 [/SUP], Adeleh Azizi[SUP] 44 [/SUP], Sajad Pouryousef[SUP] 45 [/SUP], Alijan Tabarraei[SUP] 46 [/SUP], Abdolvahab Moradi[SUP] 46 [/SUP], Sadeghali Azimi[SUP] 46 [/SUP], Yousef Yahyapour[SUP] 47 [/SUP], Masoumeh Bayani[SUP] 47 [/SUP], Vahdat Poortahmasebi[SUP] 48 [/SUP], Mojtaba Varshochi[SUP] 48 [/SUP], Masood Ziaee[SUP] 49 [/SUP], Shokouh Ghafari[SUP] 49 [/SUP], Davod Javanmard[SUP] 49 [/SUP], Alireza Soleimani[SUP] 50 [/SUP], Sayed-Hamidreza Mozhgani[SUP] 51 [/SUP], Zakiye Mokhames[SUP] 52 [/SUP], Zohreh Akhoundimeybodi[SUP] 53 [/SUP], Akram Astani[SUP] 53 [/SUP], Alireza Abdollahi[SUP] 54 [/SUP], Azar Hadadi[SUP] 55 [/SUP], Mohammad Reza Salehi[SUP] 55 [/SUP], Mahboubeh Hajiabdolbaghi[SUP] 55 [/SUP], Seyed Reza Raeeskarami[SUP] 56 [/SUP], Samira Kafan[SUP] 37 [/SUP], Mahnaz Montazeri[SUP] 55 [/SUP], Marzieh Pazoki[SUP] 37 [/SUP], Taghi Riahi[SUP] 57 [/SUP], Mahshid Talebi-Taher[SUP] 58 [/SUP], Angila Ataei-Pirkooh[SUP] 59 [/SUP], Farah Bokharaei-Salim[SUP] 59 [/SUP], Seyed Hamid Reza Faiz[SUP] 60 [/SUP], Saeed Kalantari[SUP] 61 [/SUP], Zeinab Yasin[SUP] 61 [/SUP], Seyed Mohammad Jazayeri[SUP] 2 [/SUP]
Affiliations
Background and aims: This study aims to examine the prevalence and progression of coagulation disorders in adult COVID-19 patients and evaluate the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on coagulation markers.
Methods: This retrospective study included 1885 hospitalized COVID-19 patients, aged 20 to over 90 years, from January 23, 2020, to March 9, 2021, across 23 centers in 13 provinces in Iran. Patients were categorized into three epidemiological peaks corresponding to different pandemic waves and SARS-CoV-2 variants (wild-type, B.1.36, and B.1.1.413). Data collection and statistical analysis adhered to the Iranian Center for Disease Control guidelines, with laboratory assessments focusing on hematologic and coagulation markers, including prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet (PLT) count, and Hemoglobin (Hb). Parameters were assessed to monitor coagulation dynamics and thrombotic risk over time and across epidemic waves. Estimated marginal means enabled evaluation of biomarker fluctuations by time and sex.
Results: The majority of patients were below 70 years of age, with hypertension and diabetes as common underlying conditions. The study revealed a trend of increasing white blood cells, neutrophils, neutrophil-to-lymphocyte ratio, and PLTs during the initial week. Conversely, hemoglobin and lymphocytes exhibited a downward trend. PLT, lymphocyte, and neutrophil levels were not significantly affected by sex, age groups, or different peaks. Notably, hospitalized patients exhibited prolonged PT and aPTT. Overall, 81.1% of patients recovered, while 18.9% succumbed to the disease.
Conclusion: This multicenter study provides valuable insights into the coagulation dynamics of COVID-19 patients, highlighting specific coagulation disorders associated with SARS-CoV-2. The findings emphasize the importance of monitoring coagulation markers for effective patient management and treatment decisions. Understanding how genetic and non-genetic factors influence outcomes is crucial for comprehensive care. Standardized data collection across centers strengthens the study's reliability.
Keywords: COVID‐19; SARS‐CoV‐2; coagulation; pandemic; respiratory infection.
. 2026 Apr 20;9(4):e72390.
doi: 10.1002/hsr2.72390. eCollection 2026 Apr.
Different SARS-CoV-2 Subvariants and Coagulation Markers Trend: A Retrospective Multicentric Study From Iranian Network for Research in Viral Diseases (INRVD)
Alireza Razavi[SUP] 1 [/SUP], Masoud Pourghahramani Koltapeh[SUP] 2 [/SUP], Tina Nazari[SUP] 3 [/SUP], Arefe Morvaridi[SUP] 4 [/SUP], Behrooz Banivaheb[SUP] 5 6 7 [/SUP], Sepideh Saeb[SUP] 8 [/SUP], Melina Moulaeian[SUP] 9 [/SUP], Alireza Zakaryaei[SUP] 10 [/SUP], Arash Sabzalian[SUP] 11 [/SUP], Maedeh Raei[SUP] 12 [/SUP], Bahar Razavi[SUP] 13 [/SUP], Saeed Motlaghzadeh[SUP] 14 [/SUP], Somayeh Sadat Hosseini[SUP] 15 [/SUP], Hassan Karami[SUP] 15 [/SUP], Parsa Ghafari[SUP] 15 [/SUP], Amir Aboofazeli[SUP] 15 [/SUP], Sogol Nastarvand[SUP] 9 [/SUP], Negin Kaseb Navaz Sarabi[SUP] 9 [/SUP], Alex Avakian[SUP] 9 [/SUP], Sara Ebadinejad[SUP] 16 [/SUP], Tara Keyhani[SUP] 17 [/SUP], Parand Danafar[SUP] 18 [/SUP], Rozhin Rahimlou[SUP] 19 [/SUP], Sedigheh Heidarian[SUP] 20 [/SUP], Mozhgan Mondeali[SUP] 21 [/SUP], Fatemeh Nafe-Monfared[SUP] 2 [/SUP], Mobina Jafarpour[SUP] 2 [/SUP], Marziyeh Samiee[SUP] 22 [/SUP], Fatemeh Birang[SUP] 22 [/SUP], Amirhossein Mirzazadeh[SUP] 22 [/SUP], Seyed Ariana Feiz Abadi[SUP] 22 [/SUP], Khabat Barkhordari[SUP] 2 [/SUP], Saba Siavoshi[SUP] 23 [/SUP], Mahdi Biklari[SUP] 24 [/SUP], Mohammad Khodabakhsh[SUP] 24 [/SUP], AmirHossein Javadi[SUP] 24 [/SUP], Samaneh Mirzaee[SUP] 2 [/SUP], Farshideh Didgar[SUP] 25 [/SUP], Mostafa Etebari[SUP] 25 [/SUP], Saedeh Soltanmohamad[SUP] 25 [/SUP], Babak Shahbaz[SUP] 2 [/SUP], Ebrahim Kord[SUP] 26 [/SUP], Seyed Mohammad Hashemi Shahri[SUP] 26 [/SUP], Majid Ebrahimzade[SUP] 26 [/SUP], Alireza Ansari Moghaddam[SUP] 27 [/SUP], Fariba Shahraki Sanavi[SUP] 27 [/SUP], Afagh Moattari[SUP] 28 [/SUP], Fahime Edalat[SUP] 28 [/SUP], Majid Fardi Sheijani[SUP] 28 [/SUP], Mohsen Moghadami[SUP] 29 [/SUP], Tofigh Yaghubi[SUP] 30 [/SUP], Ali Mojtahedi[SUP] 31 [/SUP], Abtin Heidarzadeh[SUP] 32 [/SUP], Mohammadreza Naghipour[SUP] 33 [/SUP], Maryam Sharifi Luyeh[SUP] 34 [/SUP], Pershang Nazemi[SUP] 35 [/SUP], Kian Alipasandi[SUP] 36 [/SUP], Maryam Albaji[SUP] 37 [/SUP], Mahdieh Afzali[SUP] 38 [/SUP], Nasim Shokouhi[SUP] 39 [/SUP], Akram Ezani[SUP] 40 [/SUP], Hamid Reza Najari[SUP] 41 [/SUP], Mirshamsedin Hosseini[SUP] 42 [/SUP], Arefeh Ghobadi[SUP] 42 [/SUP], Abdoalmabood Momeni[SUP] 42 [/SUP], Seyedeh Zeinab Fattahi[SUP] 42 [/SUP], Mehdi Mohsenzadeh[SUP] 43 [/SUP], Mohammad Jafari[SUP] 43 [/SUP], Adeleh Azizi[SUP] 44 [/SUP], Sajad Pouryousef[SUP] 45 [/SUP], Alijan Tabarraei[SUP] 46 [/SUP], Abdolvahab Moradi[SUP] 46 [/SUP], Sadeghali Azimi[SUP] 46 [/SUP], Yousef Yahyapour[SUP] 47 [/SUP], Masoumeh Bayani[SUP] 47 [/SUP], Vahdat Poortahmasebi[SUP] 48 [/SUP], Mojtaba Varshochi[SUP] 48 [/SUP], Masood Ziaee[SUP] 49 [/SUP], Shokouh Ghafari[SUP] 49 [/SUP], Davod Javanmard[SUP] 49 [/SUP], Alireza Soleimani[SUP] 50 [/SUP], Sayed-Hamidreza Mozhgani[SUP] 51 [/SUP], Zakiye Mokhames[SUP] 52 [/SUP], Zohreh Akhoundimeybodi[SUP] 53 [/SUP], Akram Astani[SUP] 53 [/SUP], Alireza Abdollahi[SUP] 54 [/SUP], Azar Hadadi[SUP] 55 [/SUP], Mohammad Reza Salehi[SUP] 55 [/SUP], Mahboubeh Hajiabdolbaghi[SUP] 55 [/SUP], Seyed Reza Raeeskarami[SUP] 56 [/SUP], Samira Kafan[SUP] 37 [/SUP], Mahnaz Montazeri[SUP] 55 [/SUP], Marzieh Pazoki[SUP] 37 [/SUP], Taghi Riahi[SUP] 57 [/SUP], Mahshid Talebi-Taher[SUP] 58 [/SUP], Angila Ataei-Pirkooh[SUP] 59 [/SUP], Farah Bokharaei-Salim[SUP] 59 [/SUP], Seyed Hamid Reza Faiz[SUP] 60 [/SUP], Saeed Kalantari[SUP] 61 [/SUP], Zeinab Yasin[SUP] 61 [/SUP], Seyed Mohammad Jazayeri[SUP] 2 [/SUP]
Affiliations
- PMID: 42023026
- PMCID: PMC13096570
- DOI: 10.1002/hsr2.72390
Background and aims: This study aims to examine the prevalence and progression of coagulation disorders in adult COVID-19 patients and evaluate the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on coagulation markers.
Methods: This retrospective study included 1885 hospitalized COVID-19 patients, aged 20 to over 90 years, from January 23, 2020, to March 9, 2021, across 23 centers in 13 provinces in Iran. Patients were categorized into three epidemiological peaks corresponding to different pandemic waves and SARS-CoV-2 variants (wild-type, B.1.36, and B.1.1.413). Data collection and statistical analysis adhered to the Iranian Center for Disease Control guidelines, with laboratory assessments focusing on hematologic and coagulation markers, including prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet (PLT) count, and Hemoglobin (Hb). Parameters were assessed to monitor coagulation dynamics and thrombotic risk over time and across epidemic waves. Estimated marginal means enabled evaluation of biomarker fluctuations by time and sex.
Results: The majority of patients were below 70 years of age, with hypertension and diabetes as common underlying conditions. The study revealed a trend of increasing white blood cells, neutrophils, neutrophil-to-lymphocyte ratio, and PLTs during the initial week. Conversely, hemoglobin and lymphocytes exhibited a downward trend. PLT, lymphocyte, and neutrophil levels were not significantly affected by sex, age groups, or different peaks. Notably, hospitalized patients exhibited prolonged PT and aPTT. Overall, 81.1% of patients recovered, while 18.9% succumbed to the disease.
Conclusion: This multicenter study provides valuable insights into the coagulation dynamics of COVID-19 patients, highlighting specific coagulation disorders associated with SARS-CoV-2. The findings emphasize the importance of monitoring coagulation markers for effective patient management and treatment decisions. Understanding how genetic and non-genetic factors influence outcomes is crucial for comprehensive care. Standardized data collection across centers strengthens the study's reliability.
Keywords: COVID‐19; SARS‐CoV‐2; coagulation; pandemic; respiratory infection.